Diffuse intrinsic pontine glioma (DIPG) remains a fatal disease and the identification and development of new treatment approaches are greatly needed. A novel computational-experimental Cancer Systems Biology approach involves identifying the interactions of master regulator (MR) proteins, with mutations and their influence on cancer development. This approach may also predict and prioritize drugs that reverse the effects of these interactions. This study will apply such an approach to evaluate new treatment strategies for patients with DIPG. Researchers will analyze the Pediatric Brain Tumor Atlas and other DIPG gene expression data using innovative computational methods. This analysis will describe the interactions of MR proteins in DIPG tumors and prioritize drugs by their ability to shut down the most aberrant MR proteins. This method can be targeted to individual patient samples and across the disease as a whole allowing for subtyping of tumors to occur while characterizing DIPG gene regulatory networks overall. This project will evaluate the efficacy of treatments predicted by the MR approach in patient-derived DIPG cell lines and animal models. This will advance drug development and suggest novel therapy approaches in DIPG to improve outcomes in this difficult-to-treat disease.
What are the goals of this project?
The main goal of this project is to advance drug and therapy development for DIPG patients through the analysis of master regulator proteins, identify subtypes of DIPG for improved therapeutics.
What is the impact of this project?
This research uses an approach that will allow for the prioritization of drugs and therapies for patients with DIPG in an effort to improve survival outcomes, provide the community a understanding of the interactions occurring between MR proteins and mutations in DIPG and provide a better understanding of subtypes of DIPG.
Why is the CBTN request important to this project?
The Pediatric Brain Tumor Atlas provides researchers with rare gene expression data from DIPG patients.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
Paul Kirk Reardon
Javad Nazarian, PhD, MSc
I am an investigator at the Center for Genetic Medicine in Children’s National Hospital in Washington, D.C., and an assistant professor in Integrative Systems Biology at the George Washington University. I received my PhD from the George Washington University in Genetics in 2005. My dissertation res
Children’s National Hospital
Children’s National HospitalJoined on
Each year, the Brain Tumor Institute at Children’s National evaluates more than 100 new patients with brain tumors, and is recognized as a world leader in childhood brain tumor care and research. Children’s National has pioneered novel pediatric brain tumor therapies, including new molecularly-targe
Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with